Atrium Therapeutics, Inc. (RNA) — SEC Filings
Atrium Therapeutics, Inc. (RNA) — 2 SEC filings. Latest: 4 (Apr 22, 2026). Includes 2 4.
View Atrium Therapeutics, Inc. on SEC EDGAR
Overview
Atrium Therapeutics, Inc. (RNA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 4 filed on Apr 22, 2026: On April 20, 2026, Steven George Hughes reported a change in beneficial ownership of securities for Atrium Therapeutics, Inc. The filing details transactions related to his holdings, but specific share counts and dollar amounts are not provided in this summary.
Sentiment Summary
Across 2 filings, the sentiment breakdown is: 2 neutral. The dominant filing sentiment for Atrium Therapeutics, Inc. is neutral.
Filing Type Overview
Atrium Therapeutics, Inc. (RNA) has filed 2 4 with the SEC between Apr 2026.
Recent SEC Filings (2)
| Date | Form | Description | Risk |
|---|---|---|---|
| Apr 22, 2026 | 4 | Steven George Hughes Reports Security Ownership Change | low |
| Apr 22, 2026 | 4 | Atrium Therapeutics Files Form 4 on Ownership Changes | low |
Risk Profile
Risk Assessment: Of RNA's 2 recent filings, 0 were flagged as high-risk, 0 as medium-risk, and 2 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Key Executives
- Steven George Hughes
- Gallagher Kathleen P.
Top Tags
insider-filing (2) · ownership-change (2)
Frequently Asked Questions
What are the latest SEC filings for Atrium Therapeutics, Inc. (RNA)?
Atrium Therapeutics, Inc. has 2 recent SEC filings from Apr 2026, including 2 4. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of RNA filings?
Across 2 filings, the sentiment breakdown is: 2 neutral. The dominant sentiment is neutral.
Where can I find Atrium Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Atrium Therapeutics, Inc. (RNA) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Atrium Therapeutics, Inc.?
Financial highlights for Atrium Therapeutics, Inc. are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.
What is the investment thesis for RNA?
Investment thesis data for RNA will be available once enriched filings are processed.
Who are the key executives at Atrium Therapeutics, Inc.?
Key executives identified across Atrium Therapeutics, Inc.'s filings include Steven George Hughes, Gallagher Kathleen P..
What are the main risk factors for Atrium Therapeutics, Inc. stock?
Of RNA's 2 assessed filings, 0 were flagged high-risk, 0 medium-risk, and 2 low-risk.
What are recent predictions and forward guidance from Atrium Therapeutics, Inc.?
Forward guidance and predictions for Atrium Therapeutics, Inc. are extracted from SEC filings as they are enriched.